Ads
related to: Treatment Macular Degeneration- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Appointment Tips
Get Tips And Useful Information
To Talk to your Retina Specialist
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Wet AMD FAQs
Search results
Q2 2024 EPS Estimates for Oculis Holding AG Cut by Analyst (NASDAQ:OCS)
ETF DAILY NEWS· 5 days agoOculis Holding AG (NASDAQ:OCS – Free Report) – Stock analysts at HC Wainwright dropped their Q2 2024 earnings per share (EPS) estimates for Oculis in a research report issued on Monday, May ...
Chardan Capital Weighs in on Ocugen, Inc.’s FY2024 Earnings (NASDAQ:OCGN)
ETF DAILY NEWS· 2 days agoOcugen, Inc. (NASDAQ:OCGN – Free Report) – Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for Ocugen in a research note issued on Wednesday, May 15th. Chardan Capital ...
HC Wainwright Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX)
ETF DAILY NEWS· 4 days agoHC Wainwright reiterated their buy rating on shares of Unity Biotechnology (NASDAQ:UBX – Free Report) in a research note released on Wednesday morning, Benzinga reports. The firm currently has ...
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Rises By 6.2%
ETF DAILY NEWS· 6 days agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling ...
BNP Paribas Financial Markets Sells 68,867 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
ETF DAILY NEWS· 5 days agoBNP Paribas Financial Markets decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 29.1% during the 4th quarter, according to the company in its most recent disclosure ...
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks· 6 days agoFree Report) reported first-quarter 2024 loss per share of 82 cents, narrower than the Zacks Consensus Estimate of a loss of $1.09. Currently, KOD does not have any approved products in its ...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
WKRN Nashville· 7 days agoKodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our ...
Ads
related to: Treatment Macular Degeneration